- Home
- PACK vs LYEL Comparison
PACK vs LYEL Comparison
Compare PACK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PACK | LYEL |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 490.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PACK | LYEL |
|---|---|---|
| Price | $3.79 | $23.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.50 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 338.1K | 79.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | $36,000.00 |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.35 | $16,285.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $2.91 | $0.39 |
| 52 Week High | $6.31 | $45.00 |
Technical Indicators
Market Signals| Indicator | PACK | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 55.91 |
| Support Level | $3.36 | $21.27 |
| Resistance Level | $3.79 | $27.30 |
| Average True Range (ATR) | 0.16 | 1.70 |
| MACD | 0.09 | 0.53 |
| Stochastic Oscillator | 71.03 | 75.83 |
Price Performance
Historical ComparisonAbout PACK Ranpak Holdings Corp
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.